Development of Drug Response Predictor (DRP) to Test Sensitivity to Investigational Anti-Cancer Drugs in Patients With Advanced Ovarian Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Ovarian Cancer
- Sponsor
- Allarity Therapeutics
- Enrollment
- 60
- Locations
- 5
- Primary Endpoint
- Identification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug
- Status
- Recruiting
- Last Updated
- 6 months ago
Overview
Brief Summary
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with histological confirmed epithelia ovarian cancer
- •Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.
- •Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting
- •FFPE tumor tissue available
Exclusion Criteria
- •Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.
- •Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator
Outcomes
Primary Outcomes
Identification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug
Time Frame: up to 2 years
based on FFPE ovarian cancer tissue
Secondary Outcomes
- Retrospective analysis of whether or not the DRP method can predict and confirm the obtained sensitivity to the prior drugs used in the treatment of ovarian cancer(up to 2 years)